The mechanism researches showed that rapamycin pre-treatment could improve inflammatory injury of the liver by suppressing the NLRP3 inflammasome activation through decreasing the levels of NLRP3, IL-1β and IL-18 in KCs of hepatic I/R injury, while 3-MA pre-treatment had the opposite effect. This evidence concerns the gene IL18 and dry eye syndrome.